CEO David King said that the acquisition of Sequenom positions LabCorp as a leader in NIPT, women's health, and reproductive genetics.
The court ordered the molecular diagnostic company to stop offering the Fetalis test it started offering in Germany this summer, which is based on Ariosa's technology.
The $302 million deal, which was expected to close by the end of the year, passed US government antitrust review in August.
The deal is still subject to other closing requirements including meeting a minimum tender condition.
Sequenom, which will be acquired by LabCorp this year, saw an increase in testing for average-risk pregnancies in the quarter, despite lower overall revenues.
A month after Brexit fears pushed the GenomeWeb Index down half a percent, companies rallied on news of an acquisition and better than expected Q2 performances.
The firm, as indicated by its agreement to acquire Sequenom, is optimistic about the prospects for NIPT.
LabCorp plans to acquire all of Sequenom's outstanding stock for $2.40 per share.
During a case management conference last week, Premaitha said the EC's competition department contacted it regarding an investigation into Illumina and Sequenom.
Although Sequenom had garnered support from a diverse range of groups who wanted clarity on patent eligibility, the Supreme Court denied the petition.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.